Hunting Bayh-Dole Vampires
The government is funding basic research at universities, not drug development. Bayh-Dole allows schools to own resulting inventions and license them for commercialization. These discoveries are more...
View ArticlePatents, Drugs and the Moral High Ground
There are millions and millions of people dying each year from all kinds of illnesses that are easily preventable using simple technologies and drugs that are off patent. None of the zealots or patent...
View ArticlePatents are Just the Start
Capitol Hill is frequently the setting for both grandstanding and pandering, and given the prevailing political and public sentiment it is also frequently a place where businesses find an inhospitable...
View ArticleThe High Cost of Making Pharmaceuticals
It is nearly universally accepted (and for a reason) that the process from discovery to market is long and costly. Drugs to not invent themselves and there are significant costs associated with nearly...
View ArticleWhen Lives Depend on Tech Transfer
Nothing clarified the stakes in orphan drug development like hearing Ron Bartek describe how after 16 years a promising treatment for his son’s disease finally emerged with TRND’s help. The therapy...
View ArticleAround and Around We Go: The Drug Development Debate
Every once and a while we get a clear example of the gulf between those battling over important public policy issues and can understand why the public and policy makers are confused by resulting...
View ArticleWhy is the Cystic Fibrosis Foundation under attack for funding the drug of...
Cystic fibrosis creates a thick, sticky mucus that builds up in the airways, causing infections, and making it difficult to breathe. Chronic pain is a common problem for patients, which increases...
View ArticleBayh-Dole Forecast: Sunny with 20% chance of Shark Attack
How tragic if the United States of America turns its patent system into a tool that rich and powerful companies use to suppress innovation that challenges their comfortable status quo. But Just because...
View ArticleBristol-Myers, AstraZeneca and AmGen maintain strong new drug pipelines
There’s been a lot of positive activity in recent months for Bristol-Myers Squibb of New York City. In early March, the U.S. Food and Drug Administration approved the use of BMS’s immunotherapy drug...
View ArticleThe looming patent nightmare facing the pharmaceutical industry
During the last hearing of the House Judiciary Committee there was an attempt to insert language via amendment that would make it impossible for Kyle Bass and others to challenge pharmaceutical patents...
View ArticleWhat ‘The Economist’ Doesn’t Get About Patents
In what can only be characterized as a bizarre, rambling, and intellectually dishonest article, 'The Economist' has inexplicably taken the position that patents are not necessary for innovation. The...
View ArticleThe Need for Regulatory Data Protection in the TPP: Why Australia’s Got it...
While patents protect innovations that are novel, nonobvious and useful, data exclusivity protects the extensive preclinical and clinical trial data required to establish new therapies as safe and...
View ArticleWill More Regulation Create Cheaper Drugs?
The idea of reducing drug prices through more government control is always simmering on the backburner and doesn’t require much to bring it to a full boil. Two recent actions turned up the heat to full...
View ArticleIP Protection Critical for BioPharma Given Number, Cost and Complexity of...
Biopharmaceutical innovation is difficult, expensive, time-consuming, and risky. More so now than ever. A 2014 study by Tufts University’s Center for the Study of Drug Development calculated that a...
View ArticleUN Access to Medicine Recommendations Will Increase Human Suffering
The pending report of the UN Secretary General's High Level Panel on Access to Medicines not only attacks the patent system as predicted, but proposes giving the organization oversight of drug...
View ArticlePublic Health and Bioscientific War on Superbugs is Hobbled by IP Uncertainties
How will our patent system treat this wonderful new discovery? How long will it take before its curative benefits can be deployed ? We can only hope that DC’s meddlers in our innovation ecosystem read...
View ArticleProperty Rights Key to Bayh-Dole Act’s Success
The focus of the political advocates pushing march-in may be lower drug costs. But the long-term costs of ripping apart IP rights are far higher and more fundamental than advocates acknowledge. The...
View ArticleWinning the Drug Development Debate
We create two new companies around academic inventions every day of the year. The critical role such companies play in drug development is clear. The successful integration of public research...
View ArticleAdvice for the Trump Administration and New Congress: Protect Bayh-Dole and...
Bayh-Dole is running on autopilot without Executive branch oversight and U.S. patents are no longer the world's gold standard. Without a course correction, we could be headed back to the bad old...
View ArticlePassage of the 21st Century Cures Act and its Potential Implications on...
With the Cures Act now signed into law, the incoming Trump administration has an opportunity to advance the broad-spectrum medical countermeasure goal set forth by the U.S. Department of Health and...
View Article
More Pages to Explore .....